Cargando…

Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways

Activation of receptor tyrosine kinase (RTK) protein is frequently observed in malignant progression of gliomas. In this study, the crosstalk activation of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) signaling pathways is demonstrated to contribute to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Xiangqi, Zhao, Yu, Han, Bo, Zha, Caijun, Zhang, Yangong, Li, Ziwei, Wu, Pengfei, Qi, Tengfei, Jiang, Chuanlu, Liu, Yang, Cai, Jinquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992617/ https://www.ncbi.nlm.nih.gov/pubmed/32001707 http://dx.doi.org/10.1038/s41467-019-14036-x

Ejemplares similares

ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma
por: Han, Bo, et al.
Publicado: (2020)

NoncoRNA: a database of experimentally supported non-coding RNAs and drug targets in cancer
por: Li, Lulu, et al.
Publicado: (2020)

Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy
por: Ming, Jianguang, et al.
Publicado: (2017)

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
por: Lin, Lin, et al.
Publicado: (2021)

DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma
por: Meng, Xiangqi, et al.
Publicado: (2019)

Roles of Long Noncoding RNAs in Conferring Glioma Progression and Treatment
por: Qin, Jie, et al.
Publicado: (2021)

Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis
por: Zha, Caijun, et al.
Publicado: (2020)

Characterization and Performance Testing of an Intumescent Nanoinhibitor for Inhibiting Coal Spontaneous Combustion
por: Huang, Zhian, et al.
Publicado: (2022)

Lnc-TALC promotes O(6)-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p
por: Wu, Pengfei, et al.
Publicado: (2019)

GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
por: Li, Jianlong, et al.
Publicado: (2016)

HK3 stimulates immune cell infiltration to promote glioma deterioration
por: Li, Shupeng, et al.
Publicado: (2023)

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
por: Yoshida, Ryohei, et al.
Publicado: (2022)

Targeting the Negative Feedback of Adenosine‐A2AR Metabolic Pathway by a Tailored Nanoinhibitor for Photothermal Immunotherapy
por: Liu, Yiqiong, et al.
Publicado: (2022)

Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases
por: Wang, Qiang, et al.
Publicado: (2023)

Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas
por: Li, Ming-Yang, et al.
Publicado: (2016)

A Voxel-Based Radiographic Analysis Reveals the Biological Character of Proneural-Mesenchymal Transition in Glioblastoma
por: Qi, Tengfei, et al.
Publicado: (2021)

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma
por: Shi, Ying, et al.
Publicado: (2021)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant EGFR in vivo
por: Nitta, Yusuke, et al.
Publicado: (2016)

Applications of brain organoids in neurodevelopment and neurological diseases
por: Sun, Nan, et al.
Publicado: (2021)

Dexamethasone and compliance affect TTFields efficacy to glioblastoma patients: a systematic review and meta-analysis
por: Li, Shupeng, et al.
Publicado: (2022)

Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma
por: Yang, Pei, et al.
Publicado: (2016)

Intelligent Nanoparticles With pH-Sensitive Co-Delivery of Temozolomide and siEGFR to Ameliorate Glioma Therapy
por: Wang, Zhen, et al.
Publicado: (2022)

DNA Damage Repair in Brain Tumor Immunotherapy
por: Zhao, Shihong, et al.
Publicado: (2022)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide
por: Li, Jing, et al.
Publicado: (2021)

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
por: Chong, Dawn Q, et al.
Publicado: (2015)

IMMU-28. IMMUNOGENOMIC ANALYSIS REVEALS LGALS1 CONTRIBUTES TO THE IMMUNE HETEROGENEITY AND IMMUNOSUPPRESSION IN GLIOMA
por: Chen, Qun, et al.
Publicado: (2020)

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
por: Kim, Seongjae, et al.
Publicado: (2023)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

20(S)‐ginsenoside‐Rg3 reverses temozolomide resistance and restrains epithelial‐mesenchymal transition progression in glioblastoma
por: Chen, Zheng, et al.
Publicado: (2018)

Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma Proliferation In Vitro
por: Matteoni, Silvia, et al.
Publicado: (2021)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
por: Ohba, Shigeo, et al.
Publicado: (2021)

Phosphorylated STYK1 restrains the inhibitory role of EGFR in autophagy initiation and EGFR-TKIs sensitivity
por: Zhou, Cefan, et al.
Publicado: (2022)

Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
por: Yang, Seung-Ho, et al.
Publicado: (2006)

The strategy for enhancing temozolomide against malignant glioma
por: Nakada, Mitsutoshi, et al.
Publicado: (2012)

Targeting autophagy to sensitive glioma to temozolomide treatment
por: Yan, Yuanliang, et al.
Publicado: (2016)

Glioma and temozolomide induced alterations in gut microbiome
por: Patrizz, Anthony, et al.
Publicado: (2020)

Temozolomide Chronotherapy in Glioma: A Systematic Review
por: Jia, Jason L., et al.
Publicado: (2023)

Targeting transferrin receptor delivery of temozolomide for a potential glioma stem cell-mediated therapy
por: Sun, Ting, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c530qcgum3friukovf6d4ok3b2